Investor Presentaiton
R&D investor presentation
34
In STEP 1, 34.8% of patients treated with semaglutide reached ≥20%
weight loss and reported improved quality of life versus placebo
Categorical weight loss
Proportion of
patients
Sema 2.4 mg showed a statistically significant treatment
difference versus placebo in the IWQOL-Lite-CT PRO
100% 92.4%
80%
60%
40%
33.1%
■Sema 2.4 mg ■Placebo
IQWOL-Lite-CT
I
74.8%
Physical function
54.8%
Physical
34.8%
Psychological
20%
11.8%
Total
5.0%
2.0%
0%
≥5%
≥10%
Weight loss
≥15%
≥20%
ETD [95% CI]
9.43 [7.50 11.35] *
9.14 [7.31 10.96] *
10.50 [8.81 12.19] *
10.02 [8.42 11.62] *
Favours placebo
Favours semaglutide
-202468
10 12 14
Descriptive statistic only. Based on the on-treatment data, i.e. data for subjects that are on-treatment
at week 68
Sema: semaglutide
* statistically significant; p-values other than physical function were not controlled for multiplicity
PRO: patient reported outcome; CI: confidence interval, ETD: estimated treatment difference, IWQOL-Lite-CT:
Impact of Weight on Quality of Life-lite:View entire presentation